ABEMACICLIB and DEATH

Overview

DEATH is the #7 most commonly reported adverse reaction for ABEMACICLIB, manufactured by Eli Lilly and Company. There are 737 FDA adverse event reports linking ABEMACICLIB to DEATH. This represents approximately 2.1% of all 35,479 adverse event reports for this drug.

Patients taking ABEMACICLIB who experience death should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

DEATH is a less commonly reported adverse event for ABEMACICLIB, but still significant enough to appear in the safety profile.

Other Side Effects of ABEMACICLIB

In addition to death, the following adverse reactions have been reported for ABEMACICLIB:

• DIARRHOEA — 5,308 reports
• FATIGUE — 2,109 reports
• NAUSEA — 1,819 reports
• VOMITING — 1,006 reports
• MALIGNANT NEOPLASM PROGRESSION — 979 reports
• DECREASED APPETITE — 820 reports
• ASTHENIA — 734 reports
• DRUG INEFFECTIVE — 697 reports
• WHITE BLOOD CELL COUNT DECREASED — 620 reports
• ANAEMIA — 602 reports

Other Drugs Associated with DEATH

The following drugs have also been linked to death in FDA adverse event reports:

Does ABEMACICLIB cause DEATH?

DEATH has been reported as an adverse event in 737 FDA reports for ABEMACICLIB. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is DEATH with ABEMACICLIB?

DEATH accounts for approximately 2.1% of all adverse event reports for ABEMACICLIB, making it a notable side effect.

What should I do if I experience DEATH while taking ABEMACICLIB?

If you experience death while taking ABEMACICLIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages